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BACKGROUND: This review of the EUROCARE-4 results attempts to separate out the early and late mortality effects contributing to
the widely reported poorer 5-year survival rates for cancer patients in the United Kingdom compared with other European countries
for 26 cancer sites.
METHODS: Patients diagnosed with cancer in 1996–1999 in 23 European countries were included in the analyses. Comparison of
1-year, 5-year and 5|1-year (i.e. only including those patients who had survived to 1 year) survival estimates between data for England
and the ‘European average’ was undertaken. This analysis was to highlight the relative contribution of early diagnosis, using
1-year survival as a proxy measure, on 5-year survival for the different sites of cancer. Three groups of cancer sites were identified
according to whether the survival differences at 1, 5 and 5|1 years were statistically significant.
RESULTS AND CONCLUSIONS: Breast cancer showed significantly poorer 1- and 5-year survival estimates in England, but the 5|1-year
survival figure was not significantly different. Thus, successful initiatives around awareness and early detection could eradicate the
survival gap. In contrast, the 5|1-year survival estimates remained significantly worse for lung, colorectal and prostate cancers, showing
that although early detection could make some difference, late effects such as treatment and management of the patients were also
influencing long-term outcome differences between England and Europe.
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It has been widely reported that 5-year survival rates for cancer
patients in the United Kingdom have, in general, lagged behind
comparator European countries (and the ‘European average’) since
the late 1970s (Berrino et al, 1995b, 1999, 2003, 2007). The NHS
Cancer Plan (Department of Health, 2000) highlighted this survival
‘gap’ and ‘catching up with Europe’ has been a major driver in
formulating national cancer policy.
High-resolution studies of a few specific sites of cancer
undertaken within some of the registries included in EURO-
CARE-2, and in which additional data on stage and diagnostic
techniques were available, suggested that later stage at presenta-
tion among UK patients was a major factor explaining the poorer
survival. These data are, however, now quite old; they relate to
cancers diagnosed in the 1980s and have not been updated (Gatta
et al, 2000; Sant et al, 2003, 2007).
The most recently published EUROCARE data, based on new
diagnoses between 1995 and 1999, indicate that the survival gap
between England and the ‘European average’ had diminished but
had not been completely removed (Berrino et al, 2007; Richards,
2007; Verdecchia et al, 2007). As a consequence, the 2007 Cancer
Reform Strategy (CRS) maintained an objective of bringing about
service improvements to reduce further the difference in survival
between England and Europe (Department of Health, 2007).
The CRS set out several initiatives to improve survival including
establishment of the National Awareness and Early Diagnosis
Initiative (NAEDI). One objective of NAEDI is to review the
evidence on links between early diagnosis and survival and
evaluate the extent to which international differences in survival
are due to differences in delays in patient presentation; in
practitioner referrals; in the availability and quality of diagnostic
techniques used; and in the management and care of patients once
diagnosed.
Use of 1-year survival as a proxy for early/late diagnosis, and
hence for stage data, has been advocated in the CRS and
comparison of this outcome measure across Europe may help
benchmark the current disparities. However, the appropriateness
of this measure will vary by cancer site and early/late presentation
is not the only possible reason for observed differences. For
example, for cancers such as oesophageal and pancreatic with a
generally poor prognosis, the introduction of chemotherapeutic
regimens for advanced disease will have improved 1-year survival
rates for patients irrespective of the proportion of early stage
tumours in the populations (Rao and Cunningham, 2008; Starling
and Cunningham, 2008; Mitry et al, 2008a,b). Also factors, such as
differences in underlying comorbidity, will impact on short-term
survival but are rarely adjusted for in comparative survival
estimates.
Use of 5-year survival data conditional on surviving 1 year (i.e.
1–5 year or 5|1 survival) has been presented in the most recent
EUROCARE-4 publications (Sant et al, 2009). Examination of this
along side 1-year survival for different cancer sites shows which
sites had variation between the countries at 1 year, which was not
present at 5 years after those who died within the first year had
been excluded from the analyses. To some extent, this enables
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bidity and either peri-operative (or postoperative treatment-
related) mortality, shown generally by the 1-year survival results,
from the effects of treatment and patient management on survival,
shown by differences in longer-term survival. This assessment is
fundamental to the NAEDI objective of trying to identify cancer
sites where delays in diagnosis have had the biggest impact on
survival and which could be targeted to reduce such delays in the
future.
This paper analyses the most recent EUROCARE data for the
more common sites of cancer, comparing outcomes in England
with the EUROCARE-4 ‘European average’ at 5, 1 and 5|1 years
after diagnosis, and also looks at recent trends in 1-year survival
data within England. This provides a means of beginning to
identify cancer sites for which the poor outcomes in England can
be attributed to later stage at diagnosis.
MATERIALS AND METHODS
The EUROCARE project has been running since 1990 (Berrino
et al, 1995a). The latest published data cover patients diagnosed
between 1996 and 1999 and are based on 2.8 million adults (aged
15–99) who were diagnosed with cancer in 23 European countries
(Sant et al, 2009). Data for 26 of the more common sites or site
groups of cancer from the EUROCARE-4 study have been
presented. The coding classification used in EUROCARE-4 is the
third revision of the International Classification of Diseases for
Oncology (ICD-O3).
The data presented here from the EUROCARE-4 study are the
figures for England and the ‘European average’, which have both
been appropriately standardised for cancer survival analyses. This
was to take into account any differences in age structures between
the countries, and four different standards are chosen depending
on the cancer site of choice. The International Cancer Survival
Standard (ICSS; Corazziari et al, 2004) was applied to the
EUROCARE-4 data, except for prostate cancer (De Angelis et al,
2009; pp 20). This differs from previous EUROCARE studies,
which used internally weighted average age structure for Europe
for that study. The ICSS gives standard weights, which should
make future comparisons easier.
Data from recent analyses within England (Rachet et al, 2009)
for 20 cancer sites or site groupings have also been included. The
classification used for this study was the tenth revision of the ICD-
10, which is not entirely comparable with those coded using ICD-
O3. These data were not originally age standardised although
equivalent age-standardised rates were made available to us
(personal communication, B Rachet, 2009). The age-standardised
data were not reported in the original paper because the authors
had found that the age distributions of the cancer patients had
changed little over the 11 years they examined. However, the
weights used in the age standardisation for the recent study in
England (Rachet et al, 2009) were different to those used in the
EUROCARE-4 publications. Instead of the ICSS weighting system,
Rachet et al (2009) used the ‘England Standard’, which is based on
the age distributions of cancer patients diagnosed between 1986
and 1990 in England (Coleman et al, 1999; pp 50). This was to
maintain comparability with previous survival analyses within
England and used a different set of weights for each of the 20
cancer sites.
The ‘European average’ survival rates reported are not strictly
true averages across the whole of Europe. This is because only 13
of the 23 countries represented in EUROCARE-4 have national
cancer registration and, hence, 100% coverage. The range of
coverage for the other countries was from 1.3% of the adult
population for Germany to 58% for Belgium. The data included in
EUROCARE-4 covered a population of just over 150 million, which
represented about 35% of the population of the combined
countries taking part in the study, and 30% of the total EU
population (excluding Norway, Switzerland and Iceland, which are
not in the EU).
The methodology used to derive the ‘European average’ was
neither a simple country-specific weighted average based on
coverage, nor one based on population, because either of these
averages would have been heavily biased. Instead, regional-specific
survival estimates were obtained by splitting Europe into five areas
and pooling the data available for the regions. This makes the
assumption that the survival for the population covered by
registration was representative of the unknown survival of the
whole region. Weighting was then applied to each of these five
regional estimates using the mean population for those countries
included in EUROCARE-4 for each region.
The method of creating the ‘European average’ led to the United
Kingdom and Ireland region making up 14.6% of the ‘European
average’. Thus, comparison of the survival estimates for England
(or indeed any other country) with the survival estimate for the
‘European average’ is not strictly straightforward, due to the
non-independence between them. However, it was assumed that
the covariance (a measure of the non-independence) between the
England value and the ‘European average’ would not be large
enough to greatly affect interpretation of statistical significance,
and as such, the difference between the survival rates for England
and the ‘European average’ for each of the 5-year, 1-year and
5|1-year estimates was obtained, along with an estimate of its
standard error (s.e.). The standard error for the survival difference
was calculated by taking the square root of the sum of the squared
standard errors obtained for each of the survival estimates for
England and the ‘European average’, ignoring the covariance
between the two cohorts.
RESULTS
Table 1 shows results for England and the ‘European average’ for 5,
1 and 5|1-year survival results for 26 of the more common sites or
site groups of cancer included in the EUROCARE-4 study. Five-
year survival was significantly worse in England for 14 of these
cancers, including the four major sites, breast, lung, colorectal and
prostate, together with cancers of the oesophagus, stomach, liver,
pancreas, cervix, ovary, kidney, brain, thyroid and multiple
myeloma. Five-year survival was significantly better in England
for head and neck cancers (including the group of oral cancers)
and malignant melanoma; and not significantly different for the
remaining 10 sites.
All of the 14 cancers showing a statistically significant worse
outcome in England at 5 years also showed a significantly worse
outcome at 1 year. A further five cancers – bone and cartilage, soft
tissue, uterus, bladder and non-Hodgkin lymphoma – also showed a
significantly worse 1-year survival, but this was not maintained at 5
years. Of the 14 cancers with significantly worse 5-year outcomes,
eight also showed a significantly worse 5|1-year survival – lung,
colorectal and prostate together with stomach, ovary, kidney and
thyroid cancers and multiple myeloma. The other six cancers had
5|1-year survival that was no longer significantly different from the
‘European average’. This group included breast cancer together with
oesophagus, liver, pancreas, cervix and brain cancers.
Table 2 shows the 14 cancers with significantly worse 5-year
outcomes ordered by the magnitude of the 5-year ‘survival gap’
between England and the ‘European average’ together with the
corresponding survival gap at 1 year and 5|1 years. Kidney cancer
showed the largest survival gap, being 12.4% worse than the
‘European average’ at 5 years, while four other sites had gaps that
were larger than 5% worse (stomach (8.4%), prostate (6.7%), ovary
(6.3%) and thyroid (5.3%)).
Of the sites for which a statistically significant gap was maintained
for 5|1-year survival, all except stomach cancer had a reduced gap in
What can we learn from recent EUROCARE results?
CS Thomson and D Forman
S103
British Journal of Cancer (2009) 101(S2), S102–S109 & 2009 Cancer Research UKcomparison with that observed from the conventional 5-year survival
analysis. For stomach cancer, survival in England was 10.5% worse
than the ‘European average’ in the 5|1-year analysis (compared
with 8.4% for the conventional 5-year outcome). Of the other sites,
only kidney (6.0%) and prostate cancer (5.1%) now had gaps of more
than 5%.
Figures 1–3 provide graphical comparisons of the differences
between England and the ‘European average’ at 5, 1 and 5|1 years.
Table 1 Patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised % relative survival (5-year,
1-year and 5|1-year)
% 5-year survival % 1-year survival % 5|1-year survival
Site
a
‘European
average’
England EC4
1995–1999
England–
‘Europe Avg’
b
‘European
average’ England
England–
‘Europe Avg’
b
‘European
average’ England
England–
‘Europe
Avg’
b
Head and neck 39.5 44.8 Sig higher 69.1 68.5 Lower 57.2 65.3 Sig higher
Oesophagus 11.1 9.9 Sig lower 35.8 32.9 Sig lower 30.9 30.1 Lower
Stomach 24.5 16.1 Sig lower 46.3 38.0 Sig lower 52.9 42.4 Sig lower
Colorectal 54.0 50.5 Sig lower 75.8 72.2 Sig lower 71.2 70.0 Sig lower
Liver 9.1 7.7 Sig lower 30.0 23.7 Sig lower 30.2 32.5 Higher
Gallbladder and
biliary tract
14.4 15.6 Higher 35.9 37.7 Higher 40.1 41.2 Higher
Pancreas 5.7 4.4 Sig lower 20.9 16.2 Sig lower 27.1 27.0 Lower
Larynx 62.8 63.9 Higher 84.7 83.7 Lower 74.1 76.4 Sig higher
Lung 12.0 8.4 Sig lower 36.0 26.9 Sig lower 33.3 31.3 Sig lower
Bone and cartilage 55.5 52.6 Lower 77.0 73.2 Sig lower 72.0 71.9 Lower
Soft tissue 59.5 58.0 Lower 80.4 78.6 Sig lower 73.9 73.8 Lower
Melanoma of skin 82.6 84.6 Sig higher 95.0 96.0 Sig higher 87.0 88.1 Sig higher
Breast
c 79.4 77.3 Sig lower 93.8 91.8 Sig lower 84.6 84.2 Lower
Cervix uteri 62.6 59.1 Sig lower 84.4 80.6 Sig lower 74.1 73.3 Lower
Corpus uteri 76.2 75.2 Lower 89.5 87.9 Sig lower 85.2 85.6 Higher
Ovary and uterine
adnexa
36.5 30.2 Sig lower 66.7 59.9 Sig lower 54.7 50.5 Sig lower
Prostate 76.4 69.7 Sig lower 92.7 90.2 Sig lower 82.4 77.3 Sig lower
Testis 89.5 89.7 Higher 93.3 93.7 Higher 96.0 95.8 Lower
Bladder 72.4 72.4 Lower 86.4 84.7 Sig lower 83.8 85.5 Sig higher
Kidney 58.0 45.6 Sig lower 73.8 62.7 Sig lower 78.6 72.6 Sig lower
Brain 19.7 17.6 Sig lower 42.7 37.1 Sig lower 46.0 47.4 Higher
Thyroid 82.9 77.6 Sig lower 87.6 83.7 Sig lower 94.6 92.8 Sig lower
Hodgkin 80.1 78.6 Lower 90.4 89.7 Lower 88.7 87.6 Lower
NHL 51.5 50.7 Lower 71.8 69.4 Sig lower 71.8 73.1 Sig higher
Multiple myeloma 35.1 30.6 Sig lower 72.3 67.1 Sig lower 48.6 45.6 Sig lower
All leukaemias 42.4 42.3 Lower 64.7 64.6 Lower 65.6 65.4 Lower
aSite groups classified according to ICD-O3 coding.
b‘Sig lower’¼England had significantly poorer survival than ‘European average’; ‘Sig higher’¼England had significantly better
survival than ‘European average’. Non-significant differences were labelled as either ‘Lower’ or ‘Higher’ based on the point estimates for England compared with ‘European
average’.
cBased on persons.
Table 2 Patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, % difference in relative survival (5-year,
1-year and 5|1-year) for the 14 sites with significantly lower 5-year survival
% difference in 5-year
survival
% difference in 1-year
survival % difference in 5|1-year survival
Site
a England–‘Europe Avg’ England–‘Europe Avg’ Difference
b England–‘Europe Avg’ Difference
b
Kidney  12.4  11.1 Sig Lower  6.0 Sig Lower
Stomach  8.4  8.3 Sig Lower  10.5 Sig Lower
Prostate  6.7  2.5 Sig Lower  5.1 Sig Lower
Ovary and uterine adnexa  6.3  6.8 Sig Lower  4.2 Sig Lower
Thyroid  5.3  3.9 Sig Lower  1.8 Sig Lower
Multiple myeloma  4.5  5.2 Sig Lower  3.0 Sig Lower
Lung  3.6  9.1 Sig Lower  2.0 Sig Lower
Colorectal  3.5  3.6 Sig Lower  1.2 Sig Lower
Cervix  3.5  3.8 Sig Lower  0.8 Lower
Breast
c  2.1  2.0 Sig Lower  0.4 Lower
Brain  2.1  5.6 Sig Lower 1.4 Higher
Liver  1.4  6.3 Sig Lower 2.3 Higher
Pancreas  1.3  4.7 Sig Lower  0.1 Lower
Oesophagus  1.2  2.9 Sig Lower  0.8 Lower
aSite groups classified according to ICD-O3 coding.
b‘Sig lower’¼England had significantly poorer survival than ‘European average’; ‘Sig higher’¼England had significantly better
survival than ‘European average’. Non-significant differences were labelled as either ‘Lower’ or ‘Higher’ based on the point estimates for England compared with ‘European
average’.
cBased on persons.
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data, for both England and the ‘European average’ for patients
diagnosed in 1995–1999, with the 1-year survival rates for England
between 1996 and 2000 reported in 2009, together with data for
2004–2006 showing changes in 1-year survival rates in England
between these two time periods. Due to the different methodo-
logies used, direct comparison between EUROCARE-4 and the
more recent England data is not strictly possible but, as expected,
for most of the cancers considered, the England results from
EUROCARE-4 are fairly similar to the more recent analysis of
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Figure 1 Five-year survival of patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised %
relative survival, ‘European average’ and England.
0
10
20
30
40
50
60
70
80
90
100
B
r
e
a
s
t
P
r
o
s
t
a
t
e
C
o
r
p
u
s
 
u
t
e
r
i
T
h
y
r
o
i
d
B
l
a
d
d
e
r
C
e
r
v
i
x
 
u
t
e
r
i
S
o
f
t
 
t
i
s
s
u
e
B
o
n
e
 
a
n
d
 
c
a
r
t
i
l
a
g
e
C
o
l
o
r
e
c
t
a
l
K
i
d
n
e
y
M
u
l
t
i
p
l
e
 
m
y
e
l
o
m
a
N
H
L
O
v
a
r
y
 
a
n
d
 
u
t
e
r
i
n
e
 
a
d
n
e
x
a
S
t
o
m
a
c
h
B
r
a
i
n
L
u
n
g
O
e
s
o
p
h
a
g
u
s
L
i
v
e
r
P
a
n
c
r
e
a
s
H
o
d
g
k
i
n
L
a
r
y
n
x
H
e
a
d
 
a
n
d
 
n
e
c
k
A
l
l
 
l
e
u
k
a
e
m
i
a
s
T
e
s
t
i
s
G
a
l
l
 
b
l
a
d
d
e
r
 
a
n
d
 
b
i
l
i
a
r
y
 
t
r
a
c
t
M
e
l
a
n
o
m
a
 
o
f
 
s
k
i
n
R
e
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
%
)
Significantly
higher Significantly lower Lower Higher
European average’ England ’
Figure 2 One-year survival of patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised %
relative survival, ‘European average’ and England.
What can we learn from recent EUROCARE results?
CS Thomson and D Forman
S105
British Journal of Cancer (2009) 101(S2), S102–S109 & 2009 Cancer Research UKEngland data for 1996–2000 (the major exception being ovarian
cancer for which the EUROCARE-4 analysis provides a 1-year
survival of 59.9% while the more recent analysis for 1996–2000
estimates 69.1%).
Of the 20 individual cancer sites or site groups considered in
Table 3 for England, 17 have shown an improvement in 1-year
survival between 1996–2000 and 2004–2006 (the exceptions being
cervical cancer (0.1% decrease), Hodgkin disease (1.4% decrease)
and leukaemia (2.3% decrease)). These improvements were
generally around 1–2% between the two time periods and the
major cancers, breast, lung, colon, rectum and prostate all showed
survival increases of this magnitude. For testicular cancer, 1-year
survival in 1996–2000 was already extremely high (97.8%) and the
improvement, by 0.1%, was marginal. The improvements in
oesophageal (5.0%), stomach (5.3%) and brain cancer (4.4%) were
the most substantial.
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Figure 3 5|1-year survival of patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised %
relative survival, ‘European average’ and England.
Table 3 Age-standardised relative survival (1-year) for patients diagnosed 1995–1999 for England and the ‘European average’ followed up to the end of
2003 (EUROCARE-4 Study); and patients diagnosed 1996–2000 and 2004–2006 in England (Rachet p. comm) followed up to the end of 2007
Site
a
‘European average’ 1995–1999
EUROCARE-4 (ICSS)
England 1995–1999
EUROCARE-4 (ICSS)
England 1996–2000 (Rachet)
(England Standard)
England 2004–2006 (Rachet)
(England Standard)
Breast 93.8
b 91.8
b 93.9
c 95.5
c
Lung 36.0 26.9 27.0
d 28.9
d
Colon 74.2 69.9 69.5
d 71.8
d
Rectum 78.7 76.3 76.1
d 78.1
d
Prostate 92.7 90.2 91.5 93.3
Oesophagus 35.8 32.9 32.8
d 37.8
d
Stomach 46.3 38.0 35.8
d 41.1
d
Pancreas 20.9 16.2 14.7
d 16.8
d
Larynx 84.7 83.7 83.7
e 85.8
e
Melanoma 95.0 96.0 95.5
d 96.6
d
Cervix 84.4 80.6 83.0 82.9
Corpus uteri 89.5 87.9 88.3 90.1
Ovary and
uterine adnexa
66.7 59.9 69.1 71.3
Testis 93.3 93.7 97.8 97.9
Kidney 73.8 62.7 67.2
d 69.7
d
Brain 42.7 37.1 33.7
d 38.1
d
NHL 71.8 69.4 71.6
d 75.2
d
Hodgkin 90.4 89.7 91.3
d 89.9
d
Multiple
myeloma
72.3 67.1 65.4
d 66.3
d
All leukaemias 64.7 64.6 63.4
d 61.1
d
aSite groups classified according to ICD-O3 coding for EUROCARE-4 but using ICD-10 coding for the England analyses by Rachet et al, 2009.
bBased on persons.
cBased
on females only.
dEstimates taken as simple averages of the male and female estimates.
eBased on males only. ICSS¼The International Cancer Survival Standard;
ICD-O3¼International Classification of Diseases for Oncology.
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Until recently, the only evidence enabling an understanding of the
reasons for the relatively poor 5-year survival outcomes in the
United Kingdom compared with elsewhere in Europe was the
EUROCARE high-resolution studies (Gatta et al, 2000; Sant et al,
2003, 2007). While these indicated later stage at diagnosis as being
an important explanation for part of the difference, the studies
only covered a few sites of cancer and were based on relatively
small numbers of patients diagnosed during the early 1980s. The
samples of UK patients included in these were not necessarily
representative of either their regions of residence, or the country as
a whole. Relevance to the current situation is, therefore,
questionable.
The present review of the EUROCARE-4 results cannot provide
an exhaustive evaluation of the relative contribution of stage
at diagnosis to 5-year survival on a site-by-site basis but the
analysis of 5, 1 and 5|1-year survival helps provide some overall
perspective.
Of the cancer sites considered, one important group is those
cancers for which survival in England was significantly worse than
the ‘European average’ at 5 years, but separating this into
outcomes after 1 year and between 1 and 5 years (i.e. having
survived for 1 year) indicated a statistically significant detriment
associated only with the former, but not the latter. This
implies that, for these cancers, it is low survival in the first year
after diagnosis, which gives rise exclusively to the relatively poor
overall outcome. The major site falling into this category was
breast cancer, but others in this group were cancers of the
oesophagus, liver, pancreas, cervix and brain. It is noteworthy that
this group includes both breast and cervical cancers for which the
benefit of population-based screening has long been established.
Both of these cancers are associated with a generally good
prognosis and the poor comparative survival in England is
probably best explained by relatively small subgroups of women
diagnosed with late stage disease, and not being detected by
screening.
In contrast, the results for oesophageal, pancreatic and liver
cancers, all with an extremely poor prognosis, may be explained in
part by differences in access to new therapeutic regimens for
advanced disease, which may have started use in England later
than elsewhere in Europe (Mitry et al, 2008a,b; Rao and
Cunningham, 2008; Starling and Cunningham, 2008; Rimassa
and Santoro, 2009). As a group, however, these cancers are often
diagnosed at an advanced, incurable stage. If registration and
follow-up of cases registered initially through death certificates
were more effective in England than elsewhere, this would result in
other countries having a higher proportion of cases that are more
likely to be registered only through death certification and/or as
cancers with an unknown primary site. These cases have very poor
outcomes but need to be excluded from survival analyses. This
would result in the poorer 1-year survival observed in England, but
would not influence the 5|1-year survival. Finally brain cancer,
associated with moderate prognosis, is a type of cancer with a
potential for early diagnosis if prompt attention is paid to
symptoms and appropriate diagnostic facilities are available. With
the exception of cervical cancer (marginal decrease) and liver
cancer (not included in the analysis by Rachet et al, (2009)), all of
the cancers in this group have shown recent improvements in 1-
year survival in England (Table 3).
A second group of cancers comprises those that showed
significantly lower survival at 1 year in England compared with
the ‘European average’, which was no longer evident at either 5 or
5|1 years. The five cancers in this group were bone and cartilage,
soft tissue, uterus, bladder and non-Hodgkin lymphoma and, as
with the preceding group, differences in early diagnosis and/or
initial management of advanced disease would explain the
disadvantage observed in England compared with the ‘European
average’, although this is not translated into a differential at 5
years. All of these cancers are associated with reasonable survival
rates overall and thus might benefit most from efforts towards
earlier diagnosis. With bladder cancer, there is also the additional
problem that changes in coding schemes defining the classification
of invasive tumours and introduced at different times in different
countries, may introduce artefactual survival differences.
The final group of eight cancers are those that had significantly
lower survival rates in England at 5 years, which were also evident
at both 1 year and 5|1 years. This group included the three
common cancers of the lung, colorectum and prostate, as well as
cancers of the kidney, thyroid, ovary and stomach and multiple
myeloma. The results for these cancers suggest that improving the
stage at diagnosis of these cancers would not have eradicated all of
the variation observed in 5-year survival between England and
Europe. There may also have been differences in the treatment
given or the management of services that affected the longer-term
outcome. However, the survival gap for all of these sites, except
stomach, was smaller between 1–5 years than it was between
diagnosis and 5 years (Table 2) indicating a role for earlier
diagnosis. In addition, all of these cancers (except thyroid that was
not analysed by Rachet et al, 2009) have shown recent improve-
ments in 1-year survival in the England data (Table 3). Prostate
cancer survival results are particularly difficult to interpret given
the unknown impact of differing intensity of PSA testing in
different countries leading to overdiagnosis of non-fatal disease.
Coding changes for the classification of invasive behaviour for
ovarian cancer make comparisons over time problematic and are
most apparent when using the different coding classifications ICD-
O3 and ICD-10, as in Table 3.
This analysis dissects the EUROCARE-4 results to discriminate,
among those cancers for which 5-year survival in England seemed
to be lagging behind Europe, those for which the explanation
seems to be largely due to effects within the year after diagnosis
(group one, not showing detrimental 5|1–year outcomes) and
those for which the explanation is related to short-
and longer-term effects (group three, showing detrimental 1 and
5|1–year outcomes). There is also a group of cancers for which
5-year survival in England was not statistically different from
the ‘European average’, but for which there was a detrimental
effect at 1 year (group two). It should also be noted that, for 10 of
the 26 cancer sites listed in Table 3, there was no statistical
difference between the England outcomes and the ‘European
average’ at 5 years, and for only two cancers (head and neck and
malignant melanoma), England had significantly better survival
than Europe.
Efforts and interventions directed towards increased cancer
awareness and earlier detection, if successful, are likely to benefit
all forms of cancer. Relative improvements to 1-year survival in
England are likely to benefit those cancers in groups one and two
to such an extent that the survival gap with Europe could almost
completely be overcome. NAEDI could make this improvement to
most of the cancers in these two groups although, for the poor
prognosis sites (oesophageal, stomach and liver), life-extending
therapies for advanced disease must also have a role. NAEDI could
also have an important function in the cancers in group three,
although the current survival gap between England and Europe for
these cancers is not fully explained by short-term survival
differences and other factors will thus also have a role.
This study has several limitations. It is acknowledged that the
non-independence between the survival estimates for England and
the ‘European average’ means that the method of testing
differences between the survival estimates, using only the pooled
variance to highlight significant differences, is not perfect. It
should, however, be sufficient to help identify which sites require
further efforts to separate out the early and late mortality effects
and where future international benchmarking projects should be
considered.
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completeness across the EUROCARE-4 data sets, presenting
indicators of quality known to affect survival analyses. One of
these measures is the percentage of registrations made solely on
the basis of death certificates (DCOs), which are excluded from the
survival calculations thus biasing the results. High DCO rates are
associated with over-inflation of the survival estimates (Berrino
et al, 1995a), and the higher DCO rates in England compared with
Europe (6.1% compared with 2.7%) suggest this is a factor which
needs consideration and a possible correction could be applied to
survival estimates (Silcocks and Thomson, 2009).
The concept of the ‘European average’ is itself problematic
mainly because the EUROCARE-4 Study only covers a minority
(about 30%) of the EU population. From the variation within the
countries with partial coverage, it is likely that the national
estimates for some of these countries would change if 100%
population coverage were available, thus, in turn, affecting the
‘European average’. Another problem with the ‘European average’
is that it assumes that all the data sets used in its estimation are of
equal quality in terms of accuracy and completeness of recording
both incident cases and subsequent deaths. Further discussion of
this is provided in both Møller et al (2009) and Abdel-Rahman
et al (2009).
An alternative to using the ‘European average’ for comparison
with England would be to identify specific populations with which
to compare the results from England; these are likely to be with
countries where comparable quality of data to those in England
was assured. This is the basis of the future proposed international
benchmarking studies.
These results also only give a crude assessment of the possible
effects of stage, early diagnosis and treatment on outcomes. A
better way to examine these effects is to include this information,
when it has been collected robustly, directly in the survival
analyses. The high-resolution studies, undertaken as part of the
earlier EUROCARE studies, attempted this but, partly because of
resource constraints involved in data collection, are not available
for contemporary comparisons.
Another weakness currently faced is that though it is known how
survival has improved in England during the past decade, how this
compares with improvements made across Europe is not known. It
is possible that the gaps are closing but have not been fully
eradicated, and without further studies this cannot be determined
for certain (Berrino et al, 2007; Richards, 2007; Verdecchia et al,
2007). This study has focussed on comparing survival within
England with the ‘European average’. It could be argued that as a
rich Western European country, England should be striving to be
the equivalent of the ‘European best’ not just as good as the
‘European average’. This was the adopted approach for estimating
the numbers of avoidable deaths in the United Kingdom relative to
the ‘European best’ (Abdel-Rahman et al, 2009).
There is, therefore, a need for new international benchmarking
studies to assess this. These studies will need to compare registry
data within England with other countries with good quality
registry data. The data collected will need to contain good staging
information, which has been robustly collected to agreed
standards, along with information about the diagnostic techniques
used, the presence of any significant comorbidity and details of the
treatment that was given. Only then may studies provide the real
understanding as to how much stage at diagnosis and earlier
detection improve cancer survival.
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